Articles tagged "Hepatocellular carcinoma"

2017 American Transplant Congress
Current Treatments for Small Hepatocellular Carcinoma: A Network Meta-Analysis of Randomized Controlled Trials.
Z. Guo, Z. Zheng, X. He, G. Chen.
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Purpose: Numerous randomized controlled trials (RCTs) concerning treatments for small hepatocellular carcinoma (HCC) have been reported. Herein, we conducted a network meta-analysis integrating current evidence…
2017 American Transplant Congress
Outcome After Living Donor Liver Transplantation for Hepatocellular Carcinoma in Elderly Patients > 65 Years: Assessing the Long Term Survival.
A. Thorat, S.-C. Hsu, L.-B. Jeng, H.-R. Yang, P.-C. Li, C.-C. Yeh, T.-H. Chen, K.-S. Poon.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan
Background:In Asia, the hepatocellular carcinoma (HCC) is most common cancer. Despite of the surveillance most tumors are diagnosed at late stages and thus HCC continues…
2017 American Transplant Congress
Multicenter Validation of a Clinicopathologic Risk Score to Predict Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4984 Patients from the US Multicenter HCC Transplant Consortium.
V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.
UCLA, LA
Objective: Recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) negatively impacts survival. Existing risk prediction models either lack external validation or limit their scope…
2017 American Transplant Congress
Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant.
T. Sandow,¹ H. Bohorquez,² D. Kirsch,¹ A. Albar,¹ P. Thevenot,³ K. Nunez,³ D. DeVun,¹ J. Gimenez,¹ G. Galliano,⁴ A. Cohen,² G. Loss,² D. Kay,¹ P. Gulotta.¹
¹Radiology, Ochsner Clinic Foundation, New Orleans, LA; ²Transplant Surgery, Ochsner Clinic Foundation, New Orleans, LA; ³Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA; ⁴Pathology, Ochsner Clinic Foundation, New Orleans, LA
Purpose:Immune factors are pivotal against disease progression after transplant in hepatocellular carcinoma (HCC). With chemoembolization (TACE) as a bridge to liver transplant, this study compares…
2017 American Transplant Congress
A Pretransplant Model Incorporating Serum Biomarkers Is Superior to the Milan Criteria in Stratifying Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4407 Patients from the US Multicenter HCC Transplant Consortium.
V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.
UCLA, LA
Objective: While adoption of the Milan Criteria (MC) has improved outcomes following liver transplantation (LT) for hepatocellular carcinoma (HCC), recurrence remains a significant challenge. We…
2017 American Transplant Congress
Re-Evaluation of Imaging Studies in Patients with Hepatocellular Carcinoma at a Transplant Center Impacts Patient Care.
A. Kardashian, B. Madani, C. Frenette.
Organ Transplant, Scripps Clinic, La Jolla, CA
Introduction: The United Network for Organ Sharing (UNOS) requires confirmation of HCC based on imaging to be made at a transplant center. This places a…
2017 American Transplant Congress
Sirolimus Prolonged Survival After Living Donor Liver Transplantation for HCC Beynd Milan Criteria; Outcome of a Multicenter Prospective Randomized Phase II Trial (ClinicalTrials.gov Identifier: NCT01374750).
K.-W. Lee,¹ S.-H. Kim,² N.-J. Yi,¹ S.-K. Hong,¹ G. Yoon,¹ H. Kim,¹ D. Oh,¹ S.-S. Han,² S.-J. Park,² K.-S. Suh.¹
¹Department of Surgery, Seoul National University, Seoul, Republic of Korea; ²Center for Liver Cancer, National Cancer Center, Goyangsi, Republic of Korea
Background:It is unclear whether the reported benefit of mTORi in LT for HCC is from direct effect of mTOR inhibitors. We aimed to compare directly…
2017 American Transplant Congress
Predicting Recurrence Prior to Transplant: The Response of HCC to Chemoembolization.
T. Sandow,¹ H. Bohorquez,² D. Kirsch,¹ P. Thevenot,³ K. Nunez,³ A. Albar,¹ D. DeVun,¹ J. Gimenez,¹ G. Galliano,⁴ A. Cohen,² G. Loss,² D. Kay,¹ P. Gulotta.¹
¹Radiology, Ochsner Clinic Foundation, New Orleans, LA; ²Transplant Surgery, Ochsner Clinic Foundation, New Orleans, LA; ³Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA; ⁴Pathology, Ochsner Clinic Foundation, New Orleans, LA
Purpose:This study assesses imaging response characteristics of patients with hepatocellular carcinoma (HCC) to chemoembolization (TACE) as a bridge to transplant and the risk of post-transplant…
2017 American Transplant Congress
HCC and Liver Transplantation Following the Recent Allocation Policy Change.
T. Ishaque, A. Massie, M. Bowring, J. Ruck, A. Cameron, B. Philosophe, D. Segev.
Johns Hopkins University, Baltimore
In October 2015, OPTN implemented a revised liver allocation policy to address the disparity between HCC and non-HCC patients in access to deceased-donor liver transplant…
2017 American Transplant Congress
Serum AFP Greater Than 200 ng/ml as a Predictor for Low Survival in Patients with Hepatocelullar Carcinoma Recurrence in a Brazilian Multicentric Study.
I. Boin,¹ M. Possatto,¹ E. Ataide,¹ R. Silva,² R. Silva,² H. Felicio,² L. Amado,³ A. Lima,³ T. Seva-Pereira.¹
¹Unit of Liver Transplantation, State University of Campinas, Campinas, SP, Brazil; ²Digestive Surgery - Liver Transplantation, Faculty of Medicine- São Jose do Rio Preto, Rio Preto, SP, Brazil; ³Digestive Surgery - Liver Transplantation, Faculty of Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil
Introduction: Liver transplantation (LT) is the only potential curative treatment for hepatocellular carcinoma (HCC) with recurrence (HCC-R) diagnosed in 16%. Aim: The objective of this…